[1
]
From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono),
and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom;
Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona
(J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales
Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in
Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the
Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon
(A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de
Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and
BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center,
Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
(S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer
Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.);
John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center,
Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology,
Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca,
Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and
the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg
School of Medicine, Chicago (M.H.).